Accord Gemcitabine Injection
PDF Leaflet Revision Date: 30 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including non-small cell lung cancer and pancreatic cancer.
Dosage (summary)
1,000 mg/mu00b2 IV infusion over 30 mins, repeated weekly for 3 weeks.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Not established; avoid in pregnancy and breastfeeding.
Key Drug Interactions
- Cisplatin
- Paclitaxel
- Radiotherapy
Contraindications
- Hypersensitivity to gemcitabine
Common side effects
- Nausea
- Vomiting
- Leucopenia
- Allergic skin rash
Counselling Points
- Monitor for signs of infection
- Avoid live vaccines
- Caution with driving due to somnolence
Serious warnings
- Severe cutaneous adverse reactions
- Haematological toxicity
- Capillary leak syndrome
- Posterior reversible encephalopathy syndrome
Important Disclaimer
The Accord Gemcitabine Injection professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
